Mason A. Israel
Mason A. Israel
Mirati Therapeutics
Verified email at mirati.com
Title
Cited by
Cited by
Year
Somatic coding mutations in human induced pluripotent stem cells
A Gore, Z Li, HL Fung, JE Young, S Agarwal, J Antosiewicz-Bourget, ...
Nature 471 (7336), 63-67, 2011
13122011
Probing sporadic and familial Alzheimer’s disease using induced pluripotent stem cells
MA Israel, SH Yuan, C Bardy, SM Reyna, Y Mu, C Herrera, MP Hefferan, ...
Nature 482 (7384), 216-220, 2012
11032012
The role of YAP transcription coactivator in regulating stem cell self-renewal and differentiation
I Lian, J Kim, H Okazawa, J Zhao, B Zhao, J Yu, A Chinnaiyan, MA Israel, ...
Genes & development 24 (11), 1106-1118, 2010
6382010
Cell-surface marker signatures for the isolation of neural stem cells, glia and neurons derived from human pluripotent stem cells
SH Yuan, J Martin, J Elia, J Flippin, RI Paramban, MP Hefferan, JG Vidal, ...
PloS one 6 (3), e17540, 2011
3572011
Investigating synapse formation and function using human pluripotent stem cell-derived neurons
JE Kim, ML O'Sullivan, CA Sanchez, M Hwang, MA Israel, K Brennand, ...
Proceedings of the National Academy of Sciences 108 (7), 3005-3010, 2011
1552011
Elucidating molecular phenotypes caused by the SORL1 Alzheimer’s disease genetic risk factor using human induced pluripotent stem cells
JE Young, J Boulanger-Weill, DA Williams, G Woodruff, F Buen, ...
Cell stem cell 16 (4), 373-385, 2015
1312015
Effect of potent γ-secretase modulator in human neurons derived from multiple presenilin 1–induced pluripotent stem cell mutant carriers
Q Liu, S Waltz, G Woodruff, J Ouyang, MA Israel, C Herrera, F Sarsoza, ...
JAMA neurology 71 (12), 1481-1489, 2014
892014
Lin− Sca1+ Kit− bone marrow cells contain early lymphoid-committed precursors that are distinct from common lymphoid progenitors
R Kumar, V Fossati, M Israel, HW Snoeck
The Journal of Immunology 181 (11), 7507-7513, 2008
632008
Capturing Alzheimer's disease genomes with induced pluripotent stem cells: prospects and challenges
MA Israel, LSB Goldstein
Genome medicine 3 (7), 1-11, 2011
252011
Sound focusing mechanism and method of estimating acoustic leakage of an object and method of estimating transmission loss of an object
BS Schnitta, MA Israel
US Patent 7,908,924, 2011
102011
Alzheimer's Disease Cellular Model for Diagnostic and Therapeutic Development
L Goldstein, M Israel
US Patent App. 13/967,682, 2014
22014
Abstract PD9-09: High tumor mutational burden (>= 10 mut/Mb) is enriched in specific breast cancer pathological subtypes
MA Israel, M Tierno, RSP Huang, K McGregor, ES Sokol, P Reddy, ...
Cancer Research 81 (4 Supplement), PD9-09-PD9-09, 2021
12021
Molecular classification of neuroendocrine tumors: Clinical experience with the 92-gene assay in> 24,000 cases.
AE Hendifar, HS Soifer, M Israel, CA Schnabel
Journal of Clinical Oncology 35 (15_suppl), e15700-e15700, 2017
12017
Method of estimating acoustic or thermal leakage of an object and method of estimating transmission loss of an object, using a sound focusing mechanism
BS Schnitta, MA Israel
US Patent 9,146,152, 2015
12015
Comparative genomic analysis of intrahepatic cholangiocarcinoma: biopsy type, ancestry and testing patterns
MA Israel, N Danziger, KA McGregor, K Murugesan, O Gjoerup, ES Sokol, ...
The oncologist, 2021
2021
Real-world (rw) clinical outcomes on alpelisib (ALP) in patients (pts) with breast cancer (BC) and PIK3CA mutations (PIK3CAm).
HS Rugo, K Raskina, AB Schrock, MA Israel, E Sokol, S Sivakumar, ...
Journal of Clinical Oncology 39 (15_suppl), 1068-1068, 2021
2021
IDH1 and IDH2 Driven Intrahepatic Cholangiocarcinoma (IHCC): A comprehensive genomic and immune profiling study.
S Makawita, MJ Borad, F Carapeto, L Kwong, TS Bekaii-Saab, ...
Journal of Clinical Oncology 39 (15_suppl), 4009-4009, 2021
2021
In search of novel synthetic lethality anti-cancer drug targets in intrahepatic cholangiocarcinoma: MTAP genomic loss.
JS Ross, AB Schrock, R Madison, N Danziger, D Pavlick, E Sokol, ...
Journal of Clinical Oncology 39 (3_suppl), 337-337, 2021
2021
Abstract P2-08-42: Use of breast cancer index to analyze tumor proliferation and endocrine responsiveness in genomic intermediate risk patients
F Yan, AK Master, MA Israel, J Liu, Y Zhang, CA Schnabel, VK Gadi
Cancer Research 79 (4 Supplement), P2-08-42-P2-08-42, 2019
2019
Use of breast cancer index to analyze tumor proliferation and endocrine responsiveness in genomic intermediate risk patients
F Yan, AK Master, MA Israel, J Liu, Y Zhang, CA Schnabel, VK Gadi
CANCER RESEARCH 79 (4), 2019
2019
The system can't perform the operation now. Try again later.
Articles 1–20